Switch theme
Sign up to access all valuation multiples
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
2003
33
LTM Revenue n/a
LTM EBITDA -$35.7M
$29.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Milestone Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of -$35.7M.
In the most recent fiscal year, Milestone Pharmaceuticals achieved revenue of n/a and an EBITDA of -$37.8M.
Milestone Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Milestone Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.0M | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$57.0M | -$37.8M | XXX | XXX | XXX |
| EBITDA Margin | -5704% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$58.4M | -$59.7M | XXX | XXX | XXX |
| Net Margin | -5839% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | $36.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Milestone Pharmaceuticals's stock price is $1.
Milestone Pharmaceuticals has current market cap of $44.4M, and EV of $29.5M.
See Milestone Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29.5M | $44.4M | XXX | XXX | XXX | XXX | $-0.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Milestone Pharmaceuticals has market cap of $44.4M and EV of $29.5M.
Milestone Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and -0.8x LTM EBITDA.
Analysts estimate Milestone Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Milestone Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $29.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | XXX | XXX |
| P/E | -1.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMilestone Pharmaceuticals's NTM/LTM revenue growth is Infinity%
Milestone Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Milestone Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Milestone Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Milestone Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -34% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Milestone Pharmaceuticals acquired XXX companies to date.
Last acquisition by Milestone Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Milestone Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Milestone Pharmaceuticals founded? | Milestone Pharmaceuticals was founded in 2003. |
| Where is Milestone Pharmaceuticals headquartered? | Milestone Pharmaceuticals is headquartered in United States of America. |
| How many employees does Milestone Pharmaceuticals have? | As of today, Milestone Pharmaceuticals has 33 employees. |
| Who is the CEO of Milestone Pharmaceuticals? | Milestone Pharmaceuticals's CEO is Mr. Joseph G. Oliveto. |
| Is Milestone Pharmaceuticals publicy listed? | Yes, Milestone Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Milestone Pharmaceuticals? | Milestone Pharmaceuticals trades under MIST ticker. |
| When did Milestone Pharmaceuticals go public? | Milestone Pharmaceuticals went public in 2019. |
| Who are competitors of Milestone Pharmaceuticals? | Similar companies to Milestone Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Milestone Pharmaceuticals? | Milestone Pharmaceuticals's current market cap is $44.4M |
| What is the current EBITDA of Milestone Pharmaceuticals? | Milestone Pharmaceuticals's last 12-month EBITDA is -$35.7M. |
| What is the current EV/EBITDA multiple of Milestone Pharmaceuticals? | Current EBITDA multiple of Milestone Pharmaceuticals is -0.8x. |
| Is Milestone Pharmaceuticals profitable? | Yes, Milestone Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
